(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.
Nautilus Biotechnology's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast NAUT's revenue for 2026 to be $90,734,302, with the lowest NAUT revenue forecast at $62,268,639, and the highest NAUT revenue forecast at $120,089,518. On average, 4 Wall Street analysts forecast NAUT's revenue for 2027 to be $991,596,306, with the lowest NAUT revenue forecast at $597,778,934, and the highest NAUT revenue forecast at $1,401,044,376.
In 2028, NAUT is forecast to generate $3,888,612,963 in revenue, with the lowest revenue forecast at $3,736,118,337 and the highest revenue forecast at $4,002,983,933.